East & North Hertfordshire NHS Trust, Lister Hospital, Stevenage, Hertfordshire, UK.
Curr Med Res Opin. 2012 Mar;28(3):371-8. doi: 10.1185/03007995.2012.657302. Epub 2012 Feb 7.
To examine the efficacy and tolerability of rosuvastatin 5 mg at daily and non-daily dosing regimens.
A retrospective survey was conducted at nine primary, secondary and tertiary healthcare centres in the United Kingdom.
Changes in lipid fractions from baseline values after more than 3 months' treatment.
A total of 325 patients were identified. These patients were aged 63 ± 10 years, 50% male and prescription was mostly for primary prevention of cardiovascular disease (CVD) (59%). Co-morbidities included: established CVD present in 41%, type 2 diabetes mellitus (15%), hypertension (74%) and smoking (9%). Adverse effects had been documented to simvastatin (75%) or atorvastatin (63%). A total of 289 patients (89%) tolerated rosuvastatin well and were still adherent after a median follow-up of 14.9 (3-79) months. The remainder (n = 36; 11%) discontinued the medication after median 5 months' treatment due to adverse effects. Efficacy was assessed in 224 patients who had adequate data. Baseline lipids were total cholesterol (TC) 7.41 ± 1.50 mmol/L, triglycerides (TG) 2.26 (range 0.36-18.4) mmol/L; high density lipoprotein cholesterol (HDL-C) 1.43 ± 0.47 mmol/L and low density lipoprotein cholesterol (LDL-C) 4.76 ± 1.38 mmol/L. Daily rosuvastatin (n = 134) reduced mean TC by 31%, TG 15% and LDL-C 43% (p < 0.001). Rosuvastatin 5 mg 2-3 times weekly (n = 79) reduced TC 26%, TG 16% and LDL-C 32% (p < 0.001). Weekly rosuvastatin (n = 11) reduced TC 17%, LDL-C by 23% (p < 0.001) but had no effect on TGs. Targets were attained in 17% of CHD-risk equivalent patients and 41% of primary prevention patients by National Cholesterol Education Program criteria and 27% and 68% using UK targets. No myositis or rhabdomyolysis was observed and alanine aminotransferase (ALT) and creatine kinase (CK) were similar to baseline.
In this retrospective observational multicentre study, rosuvastatin 5 mg was found to be safe and biochemically effective either as daily or intermittent therapy in patients intolerant to other conventional statin regimens.
研究瑞舒伐他汀 5 毫克每日和非每日剂量方案的疗效和耐受性。
在英国的九个初级、二级和三级医疗中心进行了回顾性调查。
治疗 3 个月以上后，基线值的脂质分数变化。
共确定了 325 名患者。这些患者的年龄为 63±10 岁，50%为男性，处方主要用于心血管疾病（CVD）的一级预防（59%）。合并症包括：已确诊的 CVD 占 41%，2 型糖尿病占 15%，高血压占 74%，吸烟占 9%。记录了不良反应，包括辛伐他汀（75%）或阿托伐他汀（63%）。共有 289 名（89%）患者对瑞舒伐他汀耐受良好，在中位随访 14.9（3-79）个月后仍坚持用药。其余 36 名（11%）患者因不良反应在中位治疗 5 个月后停止用药。在有足够数据的 224 名患者中评估了疗效。基线血脂为总胆固醇（TC）7.41±1.50mmol/L，甘油三酯（TG）2.26（范围 0.36-18.4）mmol/L；高密度脂蛋白胆固醇（HDL-C）1.43±0.47mmol/L 和低密度脂蛋白胆固醇（LDL-C）4.76±1.38mmol/L。每日瑞舒伐他汀（n=134）降低平均 TC 31%、TG 15%和 LDL-C 43%（p<0.001）。瑞舒伐他汀 5 毫克每周 2-3 次（n=79）降低 TC 26%、TG 16%和 LDL-C 32%（p<0.001）。每周瑞舒伐他汀（n=11）降低 TC 17%，LDL-C 23%（p<0.001），但对 TGs 没有影响。根据国家胆固醇教育计划标准，17%的冠心病风险等效患者和 41%的一级预防患者达到目标，而英国目标分别为 27%和 68%。未观察到肌炎或横纹肌溶解，丙氨酸氨基转移酶（ALT）和肌酸激酶（CK）与基线相似。
在这项回顾性观察性多中心研究中，瑞舒伐他汀 5 毫克每日或间断治疗不耐受其他常规他汀类药物治疗的患者，安全性和生化疗效良好。
